BDSX (Biodesix) EBIT per Share : $-0.31 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biodesix EBIT per Share?

Biodesix's EBIT per Share for the three months ended in Sep. 2024 was $-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.31.

During the past 3 years, the average EBIT per Share Growth Rate was 52.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biodesix's EBIT per Share or its related term are showing as below:

BDSX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -34.3 Med: -27.6 Max: 52.1
Current: 52.1

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Biodesix was 52.10% per year. The lowest was -34.30% per year. And the median was -27.60% per year.

BDSX's 3-Year EBIT Growth Rate is ranked better than
95.35% of 172 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05 vs BDSX: 52.10

Biodesix's EBIT for the three months ended in Sep. 2024 was $-8.22 Mil.

Biodesix EBIT per Share Historical Data

The historical data trend for Biodesix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix EBIT per Share Chart

Biodesix Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.61

-4.91

-1.41

-1.36

-0.52

Biodesix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.11	-0.07	-0.11	-0.07	-0.06

Biodesix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biodesix's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-42.61	/	82.113
=	-0.52

Biodesix's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.217	/	146.296
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31

Biodesix (NAS:BDSX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biodesix EBIT per Share Related Terms

Thank you for viewing the detailed overview of Biodesix's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodesix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

919 West Dillon Road, Louisville, CO, USA, 80301

Website

https://www.biodesix.com

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Executives

Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Kennedy Lawrence T. Jr	director, 10 percent owner	C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Scott Hutton	director, officer: President & CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane	officer: Chief Commercial Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano	officer: Chief Development Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie	officer: CFO, Sec'y & Treasurer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez	officer: Chief Accounting Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
John Patience	director, 10 percent owner, other: Chairman	28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Jon Faiz Kayyem	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Ryan H Siurek	officer: Chief Accounting Officer	6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Georgantas Robert William Iii	director, officer: SVP, Rsrch & Trans'l Science	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139